drugset / Trial / NCT03492996

A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace

NCT03492996

Phase 1 Completed 6 enrolled LigaChem Biosciences, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The primary objectives of the study are: • To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a \[14C\]-LCB01-0371-tracer dose to healthy subjects

Timeline

Start
2020-06-21
Primary completion
2020-08-03
Completion
2020-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Delpazolid Small molecule Oral

Indications

No indication recorded.